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STRUCTURED ABSTRACT 31 
Background: Inappropriate prescribing is a highly important problem, given the growing aging 32 
multimorbid population with associated polypharmacy. An increasing number of studies have recently 33 
developed and tested interventions to withdraw inappropriate drugs, a process called deprescribing. 34 
However, we still lack complete information on the types and prevalence of measures used to assess the 35 
success of such interventions.  36 
Objective: To categorize and synthesize the full spectrum of measures used in intervention studies 37 
focused on reducing inappropriate prescribing of chronic drugs in adults, in order to standardize 38 
measurements in future studies and help researchers design studies inclusive of the important measure 39 
types.  40 
Design: We searched Ovid/MEDLINE to identify intervention studies focused on deprescribing chronic 41 
drugs in adults, published between 2010 and 2019. 42 
Measurements: We extracted data on study characteristics, intervention components, and outcome 43 
measures. We categorized and synthesized the measures using a comprehensive and systematic 44 
framework, separating measures of intended and unintended consequences.  45 
Results: Most (90/93) studies used measures of appropriate prescribing, such as drug cessation or dose 46 
reduction. The following measures were used infrequently across studies: patient-reported experience, 47 
preferences, and outcome (12 (13%), 2 (2%), and 25 (27%) studies, respectively); provider-reported 48 
experience (11 (12%) studies); patient-provider interaction (4 (4%) studies); and measures of unintended 49 
consequences (24 (26%) studies). Studies varied in the type and number of measures assessed, ranging 50 
from 1 to 20 different measures by study.  51 
Conclusion: To ensure initiation, success, and long-term sustainability of deprescribing, it is important 52 
to assess the success of intervention studies using clinically relevant patient- and provider-centered 53 
measures. This categorized synthesis of outcome measures used in deprescribing studies may facilitate 54 
implementation of important measure types (e.g., patient reported measures, measures of unintended 55 
consequences) in future studies. 56 
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Up to 30% of medical services are considered low-value, i.e., may result in more harm than benefit.1-3 60 
Inappropriate prescribing is increasingly seen among the growing older multimorbid population,4,5 with 61 
up to one-third receiving inappropriate prescriptions.6 In response, the Choosing Wisely initiative 62 
regularly publishes recommendations to minimize low-value prescribing.1 While an increasing number 63 
of interventions focused on deprescribing inappropriate medications,7 deprescribing chronic medications 64 
remains a complex process associated with barriers at both patient and provider levels,8,9 particularly for 65 
medications, whose use was prompted by unpleasant symptoms. Fear of worsening symptoms may lead 66 
to resistance towards stopping these medications.10 Further, clinicians lack time and resources for 67 
deprescribing, report low self-efficacy for stopping therapy, and feel uncertain about clinical 68 
consequences of deprescribing (e.g., stroke following antihypertensive drug reduction).11 To ensure 69 
feasibility and sustainability of deprescribing, intervention studies should assess not only whether a 70 
medication was stopped or the dose reduced, but also patient-relevant clinical outcomes and patient and 71 
provider experience and preferences. The measures should capture both intended effects and unintended 72 
harms, a key priority identified by Choosing Wisely and patient advocates.12,13 However, deprescribing 73 
intervention studies have highly variable outcome measures and rarely include clinical outcomes, as 74 
outlined in two reviews in older adults.8,14 These reviews did not detail the types and frequency of use of 75 
the different measures, and only assessed controlled trials.8,14 This global paucity of clinical outcomes 76 
and heterogeneity of measures may be explained by a lack of guidance. It is also more challenging to 77 
collect information on experience, preferences and clinical outcome measures, as this requires longer 78 
follow-up periods, prospective designs, and broader expertise.  79 
We recently reviewed the literature to characterize measures employed in 117 interventions to reduce 80 
low-value care.15 We found that measures focused largely on utilization and rarely addressed patient-81 
centered outcomes or unintended consequences. The search strategy was not tailored to identify low-82 
value prescribing of chronic medications and included only 44 studies focused on prescribing for 83 
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predominantly acute medications (two-thirds addressed acute antibiotic use). Given the unique 84 
challenges of stopping chronic medications, the measures to assess the impact of interventions may be 85 
notably different from those used in studies focused on stopping acute medications. 86 
Based on this review, we suspected that outcome measures reported across deprescribing intervention 87 
studies for chronic medications would also lack coverage of important measure types.15 Given the lack 88 
of prior reviews, and the need to standardize outcome measures for further studies,16 we sought to 89 
provide the first review to: 1) identify measures used in recent studies evaluating the effect of 90 
interventions to reduce inappropriate prescribing of chronic medications in adults, including prescribing 91 
practices, clinical outcomes, cost/value, and patients’ and providers’ experience and interaction, and 2) 92 
categorize and synthesize these measures, using a comprehensive systematic framework, to provide 93 




Search strategy 98 
We performed a literature search in Ovid/MEDLINE search from January 1, 2010, to October 13, 2019 99 
to identify original studies of any design reporting outcome measures of interventions to reduce 100 
inappropriate prescribing of chronic drugs in adults (Supplementary Text S1). A separate search 101 
strategy was used for benzodiazepine-related drugs, without the term “appropriate prescribing” given 102 
that most use is considered inappropriate. The search was restricted to Ovid/MEDLINE, as we welt that 103 
this source alone would be sufficient to identify articles that would allow us to capture the full spectrum 104 
of available measures. Inclusion criteria were: adult population; original study (i.e., not a review or 105 
meta-analysis); intervention to reduce the use of a least one chronic inappropriate drug. We included 106 
both quantitative and qualitative studies. We excluded studies that focused on: 1) only new drug 107 
prescriptions (e.g., new prescription of proton pump inhibitor during hospitalization) or only on short-108 
term or acute drugs (e.g., antibiotic for urinary tract infection); we didn’t use a clear cut-off to define a 109 
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drug as non-chronic, as it varied depending on the drug class; 2) reducing polypharmacy in general 110 
without assessing prescribing appropriateness; 3) deprescribing as part of a global intervention not 111 
focused on reducing inappropriate prescribing; 4) inappropriate prescribing assessed globally as 112 
potentially inappropriate prescription, potential prescribing omission, inappropriate dosage or drug 113 
interactions. We focused on interventions to deprescribe chronic drugs, because the specific challenges 114 
and barriers are likely to be different than those for prescribing acute drugs or new drugs. 115 
 116 
Measure definition and categorization 117 
A measure was defined as any assessment of prescribing practice, clinical outcome, cost/value, or 118 
experience following the deprescribing intervention. We classified the measures used in the studies into 119 
several categories, adapted from a framework previously developed by our research team 120 
(Supplementary Table S1):15 1) measure specification (count, scale, proportion); 2) measure type 121 
(appropriateness, utilization/ordering, intermediate outcome, outcome, patient-reported outcome 122 
(PROM), patient-reported experience (PREM), patient preferences, provider-reported experience, 123 
patient-provider interaction, cost-related); 3) measure reporting type (patient, provider, 124 
medical/pharmacy record, validated scale/questionnaire, non-validated scale/questionnaire, blinded 125 
assessment); 4) measure of unintended consequence (including substitution of an alternative low-value 126 
drug, underuse of the drug being intervened upon, underuse of related services, PREM, provider-127 
reported experience, patient-provider interaction, patient selection, care location shift, harmful outcome, 128 
reimbursement), which were classified as “definite” if the study specifically reported it as such in the 129 
methods section, or “possible” if it was inferred by the reviewer. Appropriateness and 130 
utilization/ordering measures were further classified into subcategories: cessation, dose reduction, new 131 
prescription, switch for another drug. Utilization/ordering measures included prescribing measures not 132 
assessing the appropriateness of the drug. 133 
 134 
Data extraction  135 
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The first author (CEA) performed the literature search and used a standardized form to extract relevant 136 
data. Data on study characteristics included first author name, publication year, design, setting, 137 
participants (with specific inclusion criteria such as older age, multimorbidity, polypharmacy), number 138 
and class(es) of drug(s), and intervention aim, target (patient or provider), description and type (e.g., 139 
education, feedback, drug review). Data on measures included information required for categorization. 140 
 141 
Data analyses 142 
Separate articles referring to the same study were grouped for analysis. Similar measures across these 143 
articles were also merged. We present study characteristics as frequencies/percentage of studies (number 144 
of studies with characteristic relative to total number of studies), and measures as 145 
frequencies/percentage of measures (number of measures of a specific type relative to total number of 146 
measures) and percentage of studies, respectively. We summarized all measures used in the studies, 147 
grouping similar measures (e.g., drug cessation, intervention acceptance) used across different studies, 148 




Studies included  153 
From the 4,190 articles identified in Ovid/MEDLINE, 4,041 were excluded upon review of the title 154 
and/or abstract (Figure 1). Of the remaining 149 articles, 44 were excluded upon review of the full-text, 155 
resulting in 105 articles included in the review. Eight studies published their results through two to four 156 
separate articles, so that the total of 105 articles represents 93 unique studies. A complete list of the 105 157 
articles is provided in Supplementary Text S2.  158 
 159 
Study population, setting, design and drug classes  160 
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Most of the 93 studies (n=60, 65%) focused on older patients. Fifty-one (55%) studies were conducted 161 
in the outpatient setting, 27 (29%) in long-term care, 19 (20%) in the inpatient setting, and 8 (9%) in the 162 
pharmacy (Table 1). A control group was used in 42 (45%) studies, of which half employed 163 
randomization. The most frequent drug classes studied were sedative-hypnotics (in 64 (69%) studies) 164 
and antipsychotics (in 43 (46%) studies). Forty-two (45%) studies involved a single drug class. Study 165 
characteristics are detailed in Supplementary Table S2. 166 
 167 
Intervention characteristics 168 
The interventions were most often multifaceted and targeted a patient (in 44 (47%) studies) and/or a 169 
provider (in 85 (91%) studies). The most frequent intervention types were a review of drug 170 
appropriateness and indication in 40 (43%) studies, followed by education at the patient or provider 171 
level in 29 (31%) and 31 (33%) studies, respectively. The intervention types used in each study are 172 
detailed in Supplementary Table S2. 173 
 174 
Outcome measures characteristics within studies 175 
Across the 93 studies, we identified 511 outcome measures. We present frequencies of each measure 176 
type in Table 2. Complete drug cessation was the most frequently assessed measure, in 79 (85%) 177 
studies. Thirty-two (34%) studies used at least one patient-reported measure, including PROMs, 178 
PREMs, and patient preferences. One fourth of the studies (n=24) reported using at least one measure of 179 
unintended consequences (e.g., withdrawal symptoms or use of restraints for agitation). Non-patient 180 
reported outcome measures (e.g., hospitalizations), including intermediate outcomes (e.g., uptake of 181 
deprescribing intervention by the prescribing physician), were used in 46 (49%) studies. Provider-182 
reported experience, patient-provider interaction, and cost-related measures were rarely used. Table 3 183 
provides a synthesized and categorized list of all measures used across the studies, with some examples. 184 
The frequencies and types of measures used in each study are listed in Supplementary Table S3. 185 
 186 
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Outcome measures source within studies  187 
We present frequencies of each measure source (i.e., patient-reported, provider-reported, 188 
medical/pharmacy record, validated/non-validated scale or questionnaire, blinded assessment) in Table 189 
2. Medical or pharmacy records were the most frequent sources used for measures (86 (93%) studies). 190 
Blinded measures assessment was performed in only 11 (12%) studies (50% of the randomized trials).  191 
 192 
Appropriateness and utilization/ordering measures 193 
Thirty-four (37%) studies used both appropriateness and utilization/ordering measures (i.e., without 194 
assessing appropriateness of prescribing), while 56 studies (60%) measured only appropriateness, and a 195 
single study (1%) only utilization/ordering. Appropriateness and utilization measures included cessation, 196 
dose reduction, new prescription, and switch for another drug, either alone or in combination. For 197 
example, Ailabouni et al. evaluated the number of drugs prescribed (utilization/ordering measure) and 198 
the Drug Burden Index (appropriateness measure), while Brodaty et al. assessed cessation of 199 
inappropriate antipsychotics (appropriateness measure) and prescription rate of other psychotropic drugs 200 
(utilization/ordering measure).17,18 Studies assessing several drug classes most often reported these 201 
measures for all classes combined and for each class separately. For example, Ammerman et al. assessed 202 
discontinuation rate of any potentially inappropriate medication evaluated, as well as discontinuation 203 
rate of anticholinergics, nonsteroidal anti-inflammatory drugs, proton pump inhibitors, peripheral alpha 204 
blockers, benzodiazepines, antihistamines, and antipsychotics separately.19 205 
 206 
Patient-reported measures 207 
Twenty-five studies (27%) used PROMs, while only 12 (13%) and 2 (2%) studies assessed PREMs and 208 
patient preferences, respectively. PROMs mostly included quality of life or perceived health status, as 209 
well as drug-specific outcomes, such as sleep quality, drug dependence, cognition, sedative side effects 210 
or withdrawal/anxiety/depression symptoms for sedative-hypnotics, or gastrointestinal symptoms for 211 
proton pump inhibitors. PREMs most often evaluated a patient’s experience with the intervention (e.g., 212 
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satisfaction with educational material) or of the tapering process (e.g., reasons for tapering difficulties). 213 
Patient preferences measures included reasons for refusing deprescribing or preferences for the 214 
intervention.  215 
 216 
Provider-reported experience and patient-provider interaction measures 217 
Eleven (12%) studies evaluated provider-reported experience measures, including experience, 218 
satisfaction or acceptance of the intervention, as well as self-efficacy for deprescribing. Only 4 (4%) 219 
studies used patient-provider interaction measures, reporting the number of counseling occasions, 220 
personal interactions, discussion documentation, and drug review with the patient.  221 
 222 
Non-patient reported intermediate outcome and outcome measures 223 
Thirty-three (35%) and 19 (20%) studies included a non-patient-reported outcome or intermediate 224 
outcome measure, respectively. Intermediate outcome measures often related to acceptance rate of 225 
deprescribing recommendations. Outcome measures included healthcare services utilization 226 
(hospitalization, length of stay, ambulatory visits) and mortality. Additionally, outcome measures often 227 
included outcomes related to specific drugs (e.g., falls or confusion for sedative-hypnotics, 228 
neuropsychiatric symptoms or use of a seclusion room for antipsychotics, incidence of cardiovascular 229 
events for antihypertensive and lipid-lowering drugs). 230 
 231 
Cost-related measures 232 
Ten (11%) studies assessed effects on costs. The majority of these measured drug costs, while three 233 
(3%) evaluated the cost of the intervention (e.g., provision of educational material) and two measured 234 
the cost of healthcare services utilization. Only two (2%) studies used a value measure, specifically 235 
assessing cost-utility of the intervention.  236 
 237 
Qualitative measures 238 
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While all studies used quantitative measures, only 18 (19%) also performed a qualitative assessment. 239 
Qualitative measures included patient and provider experience, acceptance or satisfaction with the 240 
intervention assessed qualitatively (e.g., by interview), key messages remembered by providers, reasons 241 
for not deprescribing or for restarting a deprescribed drug, feasibility of the intervention, patient 242 
perception of deprescribed drugs, physician impression of deprescribing rounds, communication 243 
preferences, or decisions during discussions between patients and providers. 244 
 245 
Measures of unintended consequences 246 
Twenty-four (26%) studies reported at least one measure of unintended consequences, which 247 
represented 10% (n=52/511) of all measures. Among them, 21 were clearly mentioned as such in the 248 
methods, and thus classified as “definite,” while 31 were considered as unintended consequences by the 249 
reviewer and classified as “possible.” Unintended consequences included changes in symptoms or 250 
withdrawal related to drug tapering, use of restraints or substitute drugs, changes in laboratory 251 
parameters, as well as adverse events during deprescribing, such as hospitalization, falls, death or 252 
cardiovascular events. Of the 52 measures, outcome measures documenting unintended consequences 253 
were the most frequent (n=21, 40%), followed by PROMs (n=15, 29%), utilization/ordering measures 254 






In this review of 93 deprescribing studies, we found that almost all authors used an appropriateness 261 
measure assessing change in prescribing, most frequently drug cessation, to examine the impact of their 262 
interventions. Less often they simply used a measure of utilization or ordering, without taking into 263 
account appropriateness of medication indication and/or dosage. Less than half of the studies examined 264 
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non patient-reported outcomes, such as mortality or utilization of healthcare services. Patient-provider 265 
interaction, provider-reported experience, and cost-related measures were used infrequently and only 266 
26% of the studies evaluated unintended consequences of deprescribing.  267 
Outcome measures were uncommon and inconsistently used across all studies.  Not surprisingly, any 268 
specific measure employed was usually related to the type of intervention. For example, studies on 269 
sedative-hypnotic drugs evaluated the incidence of falls or the use of other psychotropic drugs, while 270 
studies on proton pump inhibitors assessed rebound dyspeptic symptoms or the use of a rescue drug 271 
such as a H2 blocker. Interventions with a strong focus on the patients were more likely to assess 272 
patient-reported measures, although these were present in less than one third of the studies, and 273 
measures of patient experience and preferences were particularly rare.  274 
The literature suggests that deprescribing is more likely to be successful when individual patient 275 
context, preferences, and goals are considered,20-22 particularly when patients may have withdrawal 276 
symptoms , such as for psychotropic drugs or proton pump inhibitors,23,24 and thus education and active 277 
participation for self-management is required. 278 
Although a strong focus on patient involvement is important, deprescribing remains most often initiated, 279 
directed, and sometimes required by providers, who may face multiple barriers,11 so studies should also 280 
assess the experience of the providers with the interventions. However, only a minority of authors 281 
employed provider-reported experience measures, while four studies assessed patient-provider 282 
interactions, including shared-decision making. For example, Carr et al. assessed the number of 283 
conversations around benzodiazepine cessation, and found that patients with more conversations had 284 
higher rates of deprescribing.25 Deprescribing chronic drugs may lead patients to fear or even experience 285 
withdrawal symptoms. Thus, it is important that providers understand how the patients experience 286 
potential harms and benefits of reducing the drugs, and discuss and implement deprescribing in a 287 
shared-decision-making process, a key facilitator to deprescribing.26 Future studies should more 288 
consistently assess provider experience and patient-provider interactions. Tools such as CollaboRATE 289 
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or the revised Patients’ Attitudes Towards Deprescribing questionnaire could be used for this 290 
purpose.27,28 291 
Specific barriers and facilitators for deprescribing were largely assessed by qualitative studies, mostly 292 
by interviewing or surveying patients or providers, while qualitative methods were rarely used in 293 
intervention deprescribing studies (only 18 of the 93 (19%) studies included in this review).21,29-33 294 
Qualitative research requires particular expertise and resources that differ from purely quantitative 295 
methods,34 but allows a broader assessment of barriers and facilitators, as well as patient- and provider-296 
reported experiences than quantitative measurement alone, so that it should be integrated in 297 
deprescribing intervention studies.35  298 
Withdrawing medications is recommended when harms outweigh benefits.7 However, deprescribing 299 
may result in withdrawal symptoms (e.g., sweating or irritability for benzodiazepines), return of the 300 
medical condition (e.g., heartburn for proton pump inhibitors), increased use of healthcare services, or 301 
incidence of a new condition precluded after a preventive medication is reduced (e.g., stroke for 302 
antihypertensive medications).36 It is therefore important to carefully monitor the patients during and 303 
after the deprescribing process, and to measure potentially unintended consequences, such as more 304 
frequent than expected new or recurrent symptoms, or higher healthcare services utilization.13 Our 305 
review suggests an important gap in this context, since only 27% and 35% of the authors assessed 306 
patient-reported and other outcome measures, respectively, and one fourth assessed unintended 307 
consequences of the interventions.  Finally, since some of these outcomes are infrequent or may occur 308 
only after a relatively long follow-up period, it is important to design the studies for these outcomes if 309 
important clinically. In our review, only one fourth of the interventions were randomized, with blinded 310 
measure assessment in only half of the randomized trials. 311 
We found very little overlap in the number and types of outcome measures used across the studies.  312 
Research on deprescribing will have little cumulative impact on patient care without a standardized 313 
outcome set that covers the important types relevant to deprescribing. The lack of consistency in 314 
outcome measures reported may be related to a lack of exemplars in the literature on which to base the 315 
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design of deprescribing intervention studies and the relatively recent interest in the topic. There were 316 
indeed some initial attempts to develop outcome sets in the context of deprescribing, but these focused 317 
on older patients with polypharmacy and on medication appropriateness more broadly.37,38 Thus, the 318 
results may not be generalizable to other populations or to specific medications. For example, in those 319 
studies, PROMs included cognitive functioning, patient perception of medication burden, and pain 320 
relief. Those outcome measures may be particularly pertinent for older multimorbid patients with 321 
polypharmacy, but less relevant for younger patients trying to stop proton-pump inhibitors, for example. 322 
Outcome sets for older adults also have a strong focus on medication-related outcomes, such as therapy 323 
duplication, complexity or adherence, all of which are related to polypharmacy. We did not limit our 324 
work to older or multimorbid patients with polypharmacy and used a framework to develop a broader 325 
but nonetheless synthesized set of measures for each category. This framework may serve any 326 
deprescribing intervention study and help to ensure that relevant measures across the whole spectrum, 327 
including patient- and provider-centered and unintended consequences measures, are included. 328 
We found little consistency not only in the number and types of measures considered, but also in the 329 
designs and intervention types of the studies. All these issues are important to ensure the success of 330 
deprescribing interventions. The following criteria may serve as exemplars for future researchers: 1) 331 
high evidence-based design (randomized controlled trial); 2) intervention component targeting not only 332 
the providers, but also patients; 3) broad set of measures to assess the success and acceptability of 333 
deprescribing, with both qualitative and quantitative assessment; and 4) follow-up period long enough to 334 
evaluate sustainability of deprescribing, which may provide information on scalability. The OPTI-335 
SCRIPT Study (articles numbers 2-5 in Supplementary Table S2 and Supplementary Table S3),39-42 a 336 
cluster randomized controlled trial conducted in an outpatient general care setting to deprescribe 337 
multiple potentially inappropriate drugs, is such an exemplar. The feasible intervention targeted 338 
providers (web-based algorithm, education, drug review) and patients (educational leaflets), and the 339 
authors assessed not only prescribing practices, but also clinical outcome, patient-reported experience 340 
and outcomes, provider-reported experience, and patient-provider interaction, using a mixed-method 341 
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process. In addition, patients were followed-up for 12 months and cost-utility and cost-effectiveness 342 
were evaluated. 343 
There are several limitations to this review. First, we did not grade the quality of the studies, because we 344 
focused on outcome measures and not on the effectiveness of the interventions themselves. Nonetheless, 345 
it is noteworthy that a minority of the studies were randomized and only 45% included a control group. 346 
Second, we searched only Ovid/MEDLINE. However, this search identified a large number of articles, 347 
and extending the search to other databases (e.g., EMBASE) did not significantly increase the number of 348 
relevant articles. Third, we did not review unpublished or ongoing studies, and it is possible, although 349 
unlikely, that ongoing studies are using a larger spectrum of measures. Our study also has several 350 
strengths. First, we used a broad search strategy, including specific search terms to capture interventions 351 
targeting the most frequent inappropriate drugs. This strategy was developed with a medical librarian 352 
and tested for identification of the most relevant articles. Second, we used a comprehensive and 353 
systematic categorization framework to capture a broad range of measures, including both intended and 354 
unintended consequences of the interventions. Finally, we synthesized and categorized the measures to 355 
help designers of future deprescribing intervention studies have access to the full spectrum of available 356 
measures. 357 
In conclusion, this review confirmed our hypotheses that the success of deprescribing is most 358 
consistently evaluated by drug cessation or dose reduction, while patient- and provider-reported 359 
experience, preferences and outcomes, as well as measures of unintended consequences, are 360 
infrequently considered. To ensure success and sustainability of deprescribing, it is important that 361 
intervention studies include measures that are more clinically meaningful and centered on patients and 362 
providers. To allow assessment of rare outcomes and in-depth evaluation of patient and provider 363 
preferences and experience, we suggest using a mixed-methods approach, combining a randomized 364 
controlled design with qualitative and implementation assessments. Finally, to facilitate incorporation of 365 
a broad spectrum of measures into those future studies, the synthesis and categorization of the available 366 
measures and identified gaps offers a first reference list of measures that can be useful for any 367 
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deprescribing study. Further validation of these measures by patients and providers concerned by 368 
inappropriate prescribing will ensure that measures relevant to the stakeholders are included in the 369 
process of deprescribing. 370 
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Table 1. Study characteristics (N=93) 
Total numbers for each characteristic are higher than the total number of 





Study characteristics Number (%) of studies 
Setting and patient characteristics  
  Inpatient 19 (20) 
  Long-term care 27 (29) 
  Outpatient 51 (55) 
  Pharmacy 8 (9) 
  Other (emergency department, rehabilitative care, home care) 24 (26) 
  Older patients only 60 (65) 
Methods  
  Randomized study 21 (23) 
  Control group 42 (45) 
  Quantitative assessment 93 (100) 
  Qualitative assessment 18 (19) 
Number of drug class(es) targeted by the interventions  
  1 42 (45) 
  2 13 (14) 
  3 6 (6) 
  ≥4 32 (34) 
Classes of drugs targeted by the interventions  
   Sedative-hypnotics 64 (69) 
  Antipsychotics 43 (46) 
  Antidepressants 36 (39) 
  Opioids 33 (36) 
  Anticholinergics 33 (36) 
  Proton pump inhibitors 35 (38) 
  Other drug class 35 (38) 
Intervention type  
Targeting patient 44 (47) 
  Education 29 (31) 
  Drug substitution 8 (9) 
  Other 26 (28) 
Targeting provider 85 (91) 
  Feedback / report card 9 (10) 
  Education 31 (33) 
  Guideline 20 (22) 
  Drug checklist 18 (19) 
  Drug review 40 (43) 
  Other clinical decision support 15 (16) 
  Pay for performance 1 (1) 
  Other 45 (48) 




Table 2. Types and sources of measures 
 Number (%) of measures 
Number (%) of studies with 
≥1 of the measure category / 
subcategory / source 
Measure Type   
1. Appropriateness*  211 (51) 90 (97) 
    Cessation 171 (33) 79 (85) 
    Dose reduction 68 (13) 30 (32) 
    Switch for another drug 16 (3) 5 (5) 
    New prescription 14 (3) 3 (3)  
    Other 7 (1) 1 (1) 
2. Utilization/ordering* 52 (10) 35 (38) 
    Cessation 16 (3) 10 (11) 
    Dose reduction 11 (4) 5 (5) 
    Switch for another drug 23 (5) 17 (18) 
    New prescription 21 (4) 13 (14) 
    Other 5 (1) 2 (2) 
3. Intermediate outcome** 27 (5) 19 (20) 
4. Outcome**  94 (18) 33 (35) 
5. Patient-reported outcome   62 (12) 25 (27) 
6. Patient-reported experience  15 (3) 12 (13) 
7. Patient preferences 4 (1) 2 (2) 
8. Provider-reported experience 16 (3) 11 (12) 
9. Patient-provider interaction 4 (1) 4 (4) 
10. Value (outcome/cost) 3 (1) 2 (2) 
11. Cost 12 (2) 10 (11) 
12. Other 11 (2) 10 (11) 
Measure of unintended 
consequences 52 (10) 24 (26) 
    Definite unintended consequence 21 (4) 9 (10) 
    Possible unintended consequence 31 (6) 19 (20) 
Measure source   
    Patient-reported 117 (23) 33 (36) 
    Provider-reported 75 (15) 36 (39) 
    Medical / pharmacy record 349 (68) 86 (93) 
    Validated scale / questionnaire 66 (13) 25 (27) 
    Non-validated scale / questionnaire 30 (6) 16 (17) 
    Blinded assessment 92 (18) 11 (12) 
*An appropriateness or utilization/ordering measure can be a combination of the 
subcategories, explaining that adding the subcategories results in more measures than 
the overall category. 
**Not patient reported 
Total number of measures: 511. Total number of unique studies: 93. 
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Table 3. Summary of measures used in the studies for each category and subcategory 
1. Appropriateness (a), 2. utilization/ordering (b) 
Cessation: a) number of patients with inappropriate drug ceased; b) mean number of 
prescriptions 
Dose reduction: number of patients with: a) ≥50% dose reduction of inappropriate drug; b) 
change in drug dose 
New prescription: a) number of new inappropriate drugs; b) number of drugs restarted 
(appropriateness not assessed) 
Switch for another drug: a) switches for alternative drug because of withdrawal; b) number 
with antidepressant as alternative 
3. Intermediate outcome  
Number of: deprescribing recommendations / drug alerts requiring an intervention 
Proportion of: deprescribing recommendations accepted by patients / providers 
Proportion of: patients with tapering plan developed / withdrawal attempt / receiving a 
deprescribing intervention  
Reasons for: rejecting recommendation / not achieving deprescribing 
4. Outcome  
Healthcare services utilization (e.g., length of stay, hospitalization, outpatient visit) 
Drug side effects / withdrawal signs (e.g., delirium, aggressive behavior, insomnia) 
Adverse effects of drug cessation (e.g., hyperglycemia, fall, CVD event, seclusion room, 
physical restraints, death) 
5. Patient-reported outcome  
QoL / well-being / health status (EQ-5D-3L, 15D-HRQoL, Well-Being Questionnaire, 36-
item Short Form Survey) 
Functional status / activities of daily living (Groningen Activity Restriction Scale) 
Withdrawal symptoms / drug side effects (SDS, BWSQ, Udvalg for Kliniske Undersogelser 
side effect rating scale) 
Sleep quality / satisfaction (Pittsburgh Sleep Quality Index, Oviedo Sleep Questionnaire) 
Gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale, Gastroesophageal 
Reflux Disease Impact Scale) 
Cognitive function (MoCA, MMSE, PAS-CIS; InterRAI-Long Term Care Facilities)  
Psychopathology (Brief Symptoms Inventory, Hospital Anxiety and Depression Scale, 
Geriatric Depression Scale, CES-D) 
Beliefs about drugs (Beliefs about Medicines Questionnaires) / Self-efficacy (Medication 
Reduction Self-efficacy Scale) 
6. Patient-reported experience  
Experience / satisfaction with the intervention (e.g., tapering process, implication in drug 
review, educational material) 
Difficulties during the intervention / reasons for deprescribing failure (e.g., fears because of 
prior failed attempts, withdrawal) 
7. Patient preferences 
Proportion of patients who agreed / refused deprescribing; reason(s) for refusing 
Preferences for the intervention 
8. Provider-reported experience  
Self-efficacy to deprescribe / develop a deprescribing plan / implement a deprescribing plan 
Satisfaction / experience / perception / difficulties / feasibility / acceptance / adoption / key 
messages of the intervention 
Preferences for communication between providers (e.g., face-to-face, messages through 
electronic record) 
This article is protected by copyright. All rights reserved.
4 
 
Most useful part of the intervention (e.g., reminder message, tool, patient handout) 
9. Patient-provider interaction  
Personal interactions / discussions between patients and providers regarding deprescribing 
Number of counseling occasions provided to each patient by the pharmacist / physician 
Drug review with the patient 
10. and 11. Cost-related  
10. Value (outcome/cost): cost-utility (costs/QALYs) / cost-effectiveness (costs/number of 
potentially inappropriate drugs) 
11. Costs: costs of: drugs / intervention (implementation, material (e.g., patient education 
brochure)) / healthcare services use 
Unintended consequences 
Switch for: substitute drug / additional drug / drug restarted for symptom control  
Withdrawal signs or symptoms / worsening of symptoms treated by the deprescribed drug 
Other adverse effects of deprescribing (e.g., hyperglycemia, CV events, QoL, death, fall) 
Healthcare resource utilization (e.g., length of stay, hospitalization, outpatient visits) 
Abbreviations: BWSQ, Benzodiazepine Withdrawal Symptom Questionnaire; CES-D, 
Centre for Epidemiological Studies Depression Scale; CV, cardiovascular; EQ-5D-3L, 
EuroQol five-dimensional three-level questionnaire; 15D-HRQoL, 15-dimensional health-
related quality of life instrument; MMSE, Mini-Mental State Examination; MoCA, 
Montreal Cognitive Assessment; QALY, quality-adjusted life year; QoL, quality of life; 
PAS-CIS; Psychogeriatric Assessment Scales – Cognitive Impairment Scale; SDS, 
Severity of Dependence Scale. 
Legend: Given that appropriateness and utilization/ordering measures are rather obvious 
and were ubiquitously used across studies, we only provide one example for each of their 
subcategories. For the other categories / subcategories, we synthesize all measures used 
across studies and provide examples of validated scales in brackets. Some measures are 
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